Clinical trials: Toxicity, Drug
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
RATIONALE: Chemoprotective drugs, such as calcium gluconate and magnesium sulfate, may prevent neurotoxicity caused by oxaliplatin.
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy, Neurotoxicity
- Trial name
- NCT01099449
- Testing
- calcium gluconate, magnesium sulfate, oxaliplatin
- Where
- 405 sites in United States, Puerto Rico
- Volunteers
- 362 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Anemia, Cervical Adenocarcinoma
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Anemia, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00017004
- Testing
- External Beam Radiation Therapy, Cisplatin, Internal Radiation Therapy
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Gynecologic Oncology Group
Leukemia, Cardiac Toxicity
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
It is now accepted that the anticancer properties of anthracyclines were allowed in many malignancies improve the prognosis of affected populations.
- Trial name
- CA2D (NCT01212926)
- Testing
- Echographic analysis of myocardial deformation in 2D strain
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Spinal Tumor, Spinal Hemangioma
The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma
Spinal hemangioma is one of the most common benign vertebral tumours. Being mostly asymptomatic, it is still associated with a pain syndrome especially if encroaches into the neural canal.
- Conditions
- Spinal Tumor, Spinal Hemangioma, Beta Blocker Toxicity
- Trial name
- NCT05106179
- Testing
- Atenolol Pill, Propranolol Pill
- Where
- Russia
- Volunteers
- 1,000 people
- Sponsor
- Center for Vascular Pathology, Moscow
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
This is a prospective, multicenter cohort observational; study to compare treatment outcomes in patients admitted to the hospital with Stevens-Johnsons Syndrome/Toxic Epidermolysis, aiming to assess the utility of medical…
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Reaction
- Trial name
- NCT03585946
- Testing
- Site specific standard of care comparison
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Melanoma
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site).
- Trial name
- NCT00109005
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity
Diminish Chemotherapy Related Side Effects Through Patient Education
Currently, there is a lack of patient education materials regarding cytotoxic chemotherapy side effects, research supported treatments, and the utilization of CAM by cancer patients at Penn State Cancer Institute.
- Conditions
- Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity, Chemotherapy Effect
- Trial name
- D-CRSE (NCT04694794)
- Testing
- Educational Brochure
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Milton S. Hershey Medical Center
HIV Infections
A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects
To determine the safety of ampligen at several doses in HIV-infected patients who have not yet developed AIDS or advanced AIDS related complex (ARC). Biologic, antiviral, and immunologic effects will be studied.
- Trial name
- NCT00000713
- Testing
- Ampligen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Radiotherapy; Complications, Cardiotoxicity
Multimodal Assesment of Acute Cardiac Toxicity Induced by Thoracic Radiotherapy in Cancer Patients
The purpose of this study is to evaluate and compare the changes by two modalities: Imaging by Strain by Speckle Tracking and Magnetic Resonance versus soluble markers of cardiac dysfunction as early predictors of cardio-toxicity…
- Conditions
- Radiotherapy; Complications, Cardiotoxicity, Cancer, Lung Cancer
- Trial name
- NCT04896242
- Where
- Chile
- Volunteers
- 47 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Hepatitis C, Chronic
An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C
The investigators will assess whether patients with the Hepatitis C virus (HCV) who are prescribed direct-acting antiviral (DAA) medications experience higher rates of adverse events than patients with HCV who are untreated.
- Trial name
- NCT03423641
- Testing
- Direct Acting Antivirals
- Volunteers
- 33,808 people
- Sponsor
- Kaiser Permanente
HIV Seropositivity, HIV Infections
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
Phase 3b, single arm, simplification study with dual therapy including Lamivudine (300 mg QD) plus Raltegravir (1200 mg QD) in virologically suppressed HIV-1 infected patients experiencing inconvenience, toxicity, negative impact…
- Conditions
- HIV Seropositivity, HIV Infections, HIV-1-infection
- Trial name
- NCT03333083
- Testing
- Raltegravir, Lamivudine
- Where
- Spain
- Volunteers
- 17 people
- Sponsor
- Judit Pich
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00003580
- Testing
- amifostine trihydrate, cisplatin, radiation therapy
- Where
- United States
- Sponsor
- University of Tennessee
Chemotherapeutic Toxicity, Malignant Tumor
Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by Chemotherapy
This is an open , multicenter, interventional clinical trial to conform the role of of miR-122 a real-time detection biomarker of drug-induced liver injury by chemotherapy.
- Conditions
- Chemotherapeutic Toxicity, Malignant Tumor, Liver Injury
- Trial name
- NCT03039062
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Chemotherapeutic Agent Toxicity, Infection
Using Whole-Person-Care Guide in Patients Receiving Care for Cancer or Complications From Cancer Treatment
RATIONALE: Gathering information about patients with cancer and cancer-related conditions may help doctors learn more about a patient's needs and help doctors plan the best treatment.
- Conditions
- Chemotherapeutic Agent Toxicity, Infection, Malnutrition, Musculoskeletal Complications
- Trial name
- NCT00608738
- Testing
- informational intervention, medical chart review, questionnaire administration
- Volunteers
- 750 people
- Sponsor
- Northwestern University
Breast Cancer, Cardiac Toxicity
SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This clinical trial is studying the effect of chemotherapy on heart function in treating women who…
- Trial name
- NCT00002900
- Testing
- management of therapy complications
- Where
- 105 sites in United States
- Volunteers
- 180 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve.
- Trial name
- NCT00654186
- Testing
- Revlimid
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Oncology Specialists, S.C.
Breast Cancer, Peripheral Neuropathy
Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients
Aim of the work This study aims to evaluate the possible beneficial role of silymarin in attenuating both doxorubicin related cardiac and hepatic toxicities and paclitaxel associated peripheral neuropathy and improving cognitive…
- Conditions
- Breast Cancer, Peripheral Neuropathy, Cardiac Toxicities, Hepatic Toxicity
- Trial name
- NCT05595109
- Testing
- Silymarin
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Tanta University
Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ
Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00006105
- Testing
- amifostine trihydrate, cisplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Chicago
Drug Interaction
Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine
A case control pharmacokinetic study evaluating the effects of atazanavir-ritonavir on the pharmacokinetics and toxicity of lumefantrine in people living with HIV attending APIN clinic of the Lagos University Teaching Hospital
- Trial name
- NCT04531072
- Testing
- Artemether-lumefantrine, Atazanavir-ritonavir 300/100 mg
- Where
- Nigeria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Fogarty International Center of the National Institute of Health
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
Phase I trial to study the effectiveness of oblimersen plus combination chemotherapy and dexrazoxane in treating children and adolescents who have relapsed or refractory solid tumors.
- Trial name
- NCT00039481
- Testing
- oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)